Aprepitant

Apridex is indicated for-
Prevention of postoperative nausea and vomiting (PONV)
Prevention of Chemotherapy induced nausea and vomiting (CINV)

Post Operative Nausea and Vomiting
: The recommended oral dosage of Aprepitant is 40 mg within 3 hours prior to induction of anesthesia.
Chemotherapy-Induced Nausea and Vomiting
: The following regimen should be used for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy-
Day 1
: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg 30 minutes before the start of chemotherapy.
Day 2
: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
Day 3
: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
Day 4
: Dexamethasone 8 mg orally
Aprepitant is administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3. Dexamethasone is administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. The dose of dexamethasone accounts for drug interactions.
The following regimen should be used for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
Day 1
: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg tablet 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later.
Day 2
: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
Day 3
: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day.
Aprepitant is administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3. Dexamethasone is administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for drug interactions.
Aprepitant may be taken with or without food. No dosage adjustment is necessary for the elderly patients.

Constipation, Hypotension, Pruritus, Pyrexia

Aprepitant is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors. When substance P attaches to these receptors, it causes nausea and vomiting. Aprepitant stops substance P from binding to the NK1 receptors. By blocking the receptors, Aprepitant can prevent nausea and vomiting, which often happens after chemotherapy or as a complication of surgery.